This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsRegenETP（RGTP.Q）株式概要臨床段階のバイオテクノロジー企業であるRegenETP, Inc.は、米国において、医学、生物医学工学、材料科学の各分野向けの再生組織製品および生体材料の開発・商品化を行っている。 詳細RGTP.Q ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析最新の財務報告は1年以上前のものである 意味のある時価総額がありません ( $1M )高いレベルの非現金収入 US市場と比較して、過去 3 か月間の株価の変動が非常に大きいすべてのリスクチェックを見るRGTP.Q Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.16403.2% 割高 内在価値ディスカウントEst. Revenue$PastFuture-116m15m2016201920222025202620282031Revenue US$73.0kEarnings US$13.6kAdvancedSet Fair ValueView all narrativesRegenETP, Inc. 競合他社Biodexa PharmaceuticalsSymbol: NasdaqCM:BDRXMarket cap: US$2.1mBio-Path HoldingsSymbol: OTCPK:BPTHMarket cap: US$2.1mWindtree TherapeuticsSymbol: OTCPK:WINTMarket cap: US$634.3kVincerx PharmaSymbol: OTCPK:VINCMarket cap: US$67.3k価格と性能株価の高値、安値、推移の概要RegenETP過去の株価現在の株価US$0.1652週高値US$0.2252週安値US$0.0026ベータ01ヶ月の変化1.76%3ヶ月変化11.75%1年変化668.47%3年間の変化-97.00%5年間の変化-99.41%IPOからの変化-100.00%最新ニュースお知らせ • May 21RegenETP, Inc. announced that it expects to receive $22.5 million in funding from Avenue Capital Group, LLCRegenETP, Inc. has announced that it will receive $12.5 million in a round of funding on May 20, 2024. The company will issue Common shares for the gross proceeds of $12.5 million from institutional investors and current shareholders in the transaction. The company will be provided remaining gross proceeds of $10 million in senior secured credit facility from Avenue Venture Opportunities Fund, L.P., a fund managed by Avenue Capital Group, LLC. As on the same date, the company has received $17.5 million in its first tranche. The company has received $12.5 million for the common shares and $5 million for the senior secured credit facility.お知らせ • Feb 27PolarityTE Screens First Subject in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot UlcersPolarityTE announced the Screening of the first subject in the Phase III pivotal study evaluating SkinTE in the investigational treatment of Wagner grade 1 diabetic foot ulcers (DFUs), entitled "Closure Obtained with Vascularized Epithelial Regeneration for DFUs with SkinTE II," or "COVER DFUS II." COVER DFUS II will enroll up to 120 subjects at up to 20 clinical sites in the United States. Subjects will be randomized to one of two treatment groups, receiving either SkinTE plus the standard of care (SOC) or the SOC alone. The primary endpoint is the incidence of DFUs closed at 12 weeks. Secondary endpoints include percent area reduction (PAR) at 4, 8, and 12 weeks; Total number of in-person wound care clinic visits and/or hospital days related to the index ulcer from Randomization Visit (RV1); Total days of CAM Boot use related to the index ulcer from Randomization Visit (RV1); Time to closure within 24 weeks; and Proportion of subjects experiencing treatment-emergent AEs between SOC and SkinTE arms. COVER DFUS II is a pivotal study that PolarityTE will conduct under its open IND for SkinTE.お知らせ • Aug 19+ 1 more updatePolarityTE, Inc. Announces Resignation of Jacob Patterson as Chief Financial OfficerOn August 18, 2023, Jacob Patterson, Chief Financial Officer of RegenETP, Inc. (formerly known as PolarityTE, Inc.), a Delaware corporation, informed the Company of his decision to resign effective immediately in order to pursue other opportunities.お知らせ • Aug 17+ 1 more updatePolarityTE, Inc. announced delayed 10-Q filingOn 08/15/2023, PolarityTE, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 12PolarityTE, Inc. Files Form 15PolarityTE, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.001 per share.お知らせ • Jul 08Nasdaq to Delist the Common Stock of PolarityTENasdaq announced on July 06, 2023 that it will delist the common stock of PolarityTE, Inc. The company’s securities were suspended on June 16, 2023, and have not traded on Nasdaq since that time.最新情報をもっと見るRecent updatesお知らせ • May 21RegenETP, Inc. announced that it expects to receive $22.5 million in funding from Avenue Capital Group, LLCRegenETP, Inc. has announced that it will receive $12.5 million in a round of funding on May 20, 2024. The company will issue Common shares for the gross proceeds of $12.5 million from institutional investors and current shareholders in the transaction. The company will be provided remaining gross proceeds of $10 million in senior secured credit facility from Avenue Venture Opportunities Fund, L.P., a fund managed by Avenue Capital Group, LLC. As on the same date, the company has received $17.5 million in its first tranche. The company has received $12.5 million for the common shares and $5 million for the senior secured credit facility.お知らせ • Feb 27PolarityTE Screens First Subject in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot UlcersPolarityTE announced the Screening of the first subject in the Phase III pivotal study evaluating SkinTE in the investigational treatment of Wagner grade 1 diabetic foot ulcers (DFUs), entitled "Closure Obtained with Vascularized Epithelial Regeneration for DFUs with SkinTE II," or "COVER DFUS II." COVER DFUS II will enroll up to 120 subjects at up to 20 clinical sites in the United States. Subjects will be randomized to one of two treatment groups, receiving either SkinTE plus the standard of care (SOC) or the SOC alone. The primary endpoint is the incidence of DFUs closed at 12 weeks. Secondary endpoints include percent area reduction (PAR) at 4, 8, and 12 weeks; Total number of in-person wound care clinic visits and/or hospital days related to the index ulcer from Randomization Visit (RV1); Total days of CAM Boot use related to the index ulcer from Randomization Visit (RV1); Time to closure within 24 weeks; and Proportion of subjects experiencing treatment-emergent AEs between SOC and SkinTE arms. COVER DFUS II is a pivotal study that PolarityTE will conduct under its open IND for SkinTE.お知らせ • Aug 19+ 1 more updatePolarityTE, Inc. Announces Resignation of Jacob Patterson as Chief Financial OfficerOn August 18, 2023, Jacob Patterson, Chief Financial Officer of RegenETP, Inc. (formerly known as PolarityTE, Inc.), a Delaware corporation, informed the Company of his decision to resign effective immediately in order to pursue other opportunities.お知らせ • Aug 17+ 1 more updatePolarityTE, Inc. announced delayed 10-Q filingOn 08/15/2023, PolarityTE, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 12PolarityTE, Inc. Files Form 15PolarityTE, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.001 per share.お知らせ • Jul 08Nasdaq to Delist the Common Stock of PolarityTENasdaq announced on July 06, 2023 that it will delist the common stock of PolarityTE, Inc. The company’s securities were suspended on June 16, 2023, and have not traded on Nasdaq since that time.お知らせ • Jun 17PolarityTE, Inc.(OTCPK:PTEI.Q) dropped from NASDAQ Composite IndexPolarityTE, Inc. removedNew Risk • Jun 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$22m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Shareholders have been substantially diluted in the past year (87% increase in shares outstanding). Revenue is less than US$1m (US$73k revenue). Market cap is less than US$10m (US$1.44m market cap).お知らせ • Jun 09+ 1 more updatePolarityTE's Common Stock To Be Delisted From NasdaqAs previously disclosed, on June 6, 2023, PolarityTE, Inc. (Company) and certain of its subsidiaries (collectively, the “Debtors”) filed voluntary petitions for relief (the “Chapter 11 Cases”) under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the District of Utah (Bankruptcy Court) under the captions In re PolarityTE, Inc., a Delaware corporation (Case No. 23-bk-22358-KRA) (Bankr. D. Utah), In re PolarityTE, MD Inc., a Nevada corporation (Case No. 23-bk-22360-KRA) (Bankr. D. Utah), and In re PolarityTE, Inc., a Nevada corporation (Case No. 23-bk-22361-KRA) (Bankr. D. Utah) (collectively, the “Chapter 11 Cases”). The Debtors have filed a motion with the Bankruptcy Court seeking joint administration under the caption In re PolarityTE, Inc., a Delaware corporation (Case No. 23-bk-22358-KRA) (Bankr. D. Utah). On June 7, 2023, the Company received written notice (the “Delisting Notice”) from the staff of the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, as a result of the Chapter 11 Cases and in accordance with Nasdaq Listing Rules 5101, 5110(b), and IM-5101-1, Nasdaq had determined that the Company’s common stock will be delisted from Nasdaq. The Company does not intend to appeal this determination. In addition, as previously disclosed, on October 26, 2022, the Company received a deficiency letter (the “Bid Price Notice”) from the Staff notifying the Company that the Company was not in compliance with the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In the Delisting Notice, the staff of Nasdaq referenced concerns about the Company’s ability to sustain compliance with all requirements for continued listing on Nasdaq, specifically referencing the Bid Price Notice. Trading of the Company’s common stock will be suspended at the opening of business on June 16, 2023.Reported Earnings • May 14First quarter 2023 earnings released: US$0.58 loss per share (vs US$1.12 loss in 1Q 2022)First quarter 2023 results: US$0.58 loss per share. Net loss: US$4.24m (loss widened 13% from 1Q 2022). Revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US.Reported Earnings • Mar 29Full year 2022 earnings: EPS misses analyst expectationsFull year 2022 results: US$1.14 loss per share (improved from US$9.43 loss in FY 2021). Net loss: US$7.83m (loss narrowed 74% from FY 2021). Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US.お知らせ • Jan 28Polarityte, Inc. Appoints Jeff Dyer as A Member of the Board of DirectorsPolarityTE, Inc. elected Jeff Dyer, PhD, to serve as a member of the Board of Directors beginning January 26, 2023, for a term expiring at the Company’s 2025 annual meeting of stockholders. Dr. Dyer was also appointed to serve on the Company’s Audit Committee, Nominating and Governance Committee, and Compensation Committee for which he will also serve as chairperson. Dr. Dyer served on the Company’s Board from March 2, 2017, to September 2, 2022. Dr. Dyer has served as the Horace Beesley Professor of Strategy at Brigham Young University since September 1999. From August 1993 until September 1999, he served as an Assistant Professor at Wharton School, University of Pennsylvania, and from July 1984 until September 1988 he served as Management Consultant and Manager of Bain & Company. Dr. Dyer received his Bachelor of Science degree in psychology and MBA from Brigham Young University and his PhD in management from University of California, Los Angeles. In consideration for Dr. Dyer’s agreement to join the Board the Company agreed to pay him a one-time cash fee of $10,000. In accordance with the Company’s annual compensation program for non-employee directors that began October 1, 2022, Dr. Dyer is entitled to receive a $50,000 annual retainer prorated for the period of actual service that began January 26, 2023, or a total of $33,972.60, which is paid in the form of restricted stock units issued under the Company’s equity incentive plans that will vest in arrears at the rate of 26.2% on March 31, 2023, 36.9% on June 30, 2023, and 36.9% on September 30, 2023. Dr. Dyer will be entitled be entitled to additional compensation for his service on Board committees. As chair of the Compensation Committee he is paid an annual cash fee of $7,500, payable quarterly in arrears and prorated for actual periods of service less than a full quarter. As a member of the Audit Committee Dr. Dyer is paid an annual cash fee of $4,500 and as a member of the Nominating and Governance Committee he is paid an annual cash fee of $2,500, in each case payable quarterly in arrears and prorated for periods of service less than a full quarter.Board Change • Jan 19Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. Independent Chairman of the Board Peter Cohen was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Breakeven Date Change • Jan 03Forecast to breakeven in 2025The 2 analysts covering PolarityTE expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$42.5m in 2025. Average annual earnings growth of 58% is required to achieve expected profit on schedule.Major Estimate Revision • Nov 17Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 losses forecast to reduce from -US$130 to -US$4.60 per share. Revenue forecast unchanged from US$814.0k at last update. Biotechs industry in the US expected to see average net income decline 94% next year. Consensus price target of US$1.25 unchanged from last update. Share price fell 16% to US$0.69 over the past week.Price Target Changed • Nov 16Price target decreased to US$1.25Down from US$50.00, the current price target is provided by 1 analyst. New target price is 80% above last closing price of US$0.69. The company is forecast to post a net loss per share of US$4.60 next year compared to a net loss per share of US$9.43 last year.Reported Earnings • Nov 16Third quarter 2022 earnings released: US$0.47 loss per share (vs US$0.31 loss in 3Q 2021)Third quarter 2022 results: US$0.47 loss per share (further deteriorated from US$0.31 loss in 3Q 2021). Net loss: US$3.40m (loss widened 233% from 3Q 2021). Revenue is expected to decline by 145% p.a. on average during the next 2 years, while revenues in the Biotechs industry in the US are expected to grow by 14%.Reported Earnings • Nov 12Third quarter 2022 earnings released: US$0.47 loss per share (vs US$0.31 loss in 3Q 2021)Third quarter 2022 results: US$0.47 loss per share (further deteriorated from US$0.31 loss in 3Q 2021). Net loss: US$3.40m (loss widened 233% from 3Q 2021). Revenue is expected to decline by 145% p.a. on average during the next 2 years, while revenues in the Biotechs industry in the US are expected to grow by 14%.Major Estimate Revision • Aug 18Consensus revenue estimates fall by 40%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$2.20m to US$1.32m. Forecast losses increased from -US$0.98 to -US$9.15 per share. Biotechs industry in the US expected to see average net income decline 57% next year. Consensus price target of US$39.38 unchanged from last update. Share price fell 19% to US$1.32 over the past week.Price Target Changed • Aug 13Price target decreased to US$15.38Down from US$26.88, the current price target is an average from 3 analysts. New target price is 1,014% above last closing price of US$1.38. Stock is down 93% over the past year. The company is forecast to post a net loss per share of US$0.66 next year compared to a net loss per share of US$9.43 last year.Reported Earnings • Aug 12Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2022 results: US$0.013 loss per share (up from US$0.99 loss in 2Q 2021). Revenue: US$73.0k (down 97% from 2Q 2021). Net loss: US$68.0k (loss narrowed 98% from 2Q 2021). Revenue missed analyst estimates by 85%. Earnings per share (EPS) exceeded analyst estimates by 98%. Over the next year, revenue is expected to shrink by 17% compared to a 51% growth forecast for the industry in the US.Seeking Alpha • Aug 12PolarityTE down 10% on lower-than-expected Q2 revenuePolarityTE (NASDAQ:PTE) is trading ~10% down after the company reported lower-than-expected quarterly revenue. The company said it ceased commercial sales of SkinTE in the second calendar quarter of 2021 and sold the IBEX services business, so the Company was not engaged in any revenue generating business activity at June 30, and does not expect to generate operating revenues from any business activity for the foreseeable future. The Company had cash and cash equivalents of $20.5mMajor Estimate Revision • May 23Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$2.82m to US$2.20m. EPS estimate increased from -US$6.75 to -US$0.98 per share. Biotechs industry in the US expected to see average net income decline 52% next year. Consensus price target down from US$26.88 to US$15.38. Share price fell 43% to US$2.43 over the past week.Price Target Changed • May 22Price target decreased to US$15.38Down from US$26.88, the current price target is an average from 3 analysts. New target price is 554% above last closing price of US$2.35. Stock is down 92% over the past year. The company is forecast to post a net loss per share of US$0.98 next year compared to a net loss per share of US$9.43 last year.Reported Earnings • May 17First quarter 2022 earnings: Revenues miss analyst expectationsFirst quarter 2022 results: Revenue: US$741.0k (down 84% from 1Q 2021). Net loss: US$3.77m (loss narrowed 78% from 1Q 2021). Revenue missed analyst estimates by 13%. Over the next year, revenue is expected to shrink by 47% compared to a 36% growth forecast for the industry in the US.Price Target Changed • Apr 27Price target decreased to US$1.08Down from US$2.25, the current price target is an average from 3 analysts. New target price is 478% above last closing price of US$0.19. Stock is down 82% over the past year. The company is forecast to post a net loss per share of US$0.27 next year compared to a net loss per share of US$0.38 last year.Major Estimate Revision • Apr 06Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$2.87m to US$2.82m. 2022 losses expected to reduce from -US$0.34 to -US$0.27 per share. Biotechs industry in the US expected to see average net income decline 47% next year. Consensus price target down from US$2.25 to US$1.08. Share price fell 15% to US$0.23 over the past week.Reported Earnings • Mar 31Full year 2021 earnings: EPS and revenues exceed analyst expectationsFull year 2021 results: US$0.38 loss per share (up from US$1.11 loss in FY 2020). Revenue: US$9.40m (down 7.1% from FY 2020). Net loss: US$30.2m (loss narrowed 30% from FY 2020). Revenue exceeded analyst estimates by 16%. Earnings per share (EPS) also surpassed analyst estimates by 20%. Over the next year, revenue is expected to shrink by 74% compared to a 66% growth forecast for the pharmaceuticals industry in the US.分析記事 • Mar 08Will PolarityTE (NASDAQ:PTE) Spend Its Cash Wisely?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...分析記事 • Nov 16Here's Why We're Watching PolarityTE's (NASDAQ:PTE) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Reported Earnings • Nov 12Third quarter 2021 earnings released: US$0.013 loss per share (vs US$0.18 loss in 3Q 2020)The company reported a decent third quarter result with reduced losses and improved control over expenses, although revenues were weaker. Third quarter 2021 results: Revenue: US$1.12m (down 67% from 3Q 2020). Net loss: US$1.02m (loss narrowed 86% from 3Q 2020).Executive Departure • Sep 07Independent Director Minnie Baylor-Henry has left the companyOn the 1st of September, Minnie Baylor-Henry's tenure as Independent Director ended after 2.7 years in the role. As of June 2021, Minnie still personally held 129.51k shares (US$132k worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 3.17 years.Major Estimate Revision • Aug 19Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$11.1m to US$7.69m. EPS estimate increased from -US$0.52 to -US$0.45 per share. Biotechs industry in the US expected to see average net income decline 21% next year. Consensus price target of US$2.75 unchanged from last update. Share price fell 5.0% to US$0.82 over the past week.Reported Earnings • Aug 14Second quarter 2021 earnings released: US$0.04 loss per share (vs US$0.33 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: US$2.54m (up 12% from 2Q 2020). Net loss: US$3.19m (loss narrowed 75% from 2Q 2020).Seeking Alpha • Jul 19PolarityTE Is Not A DeFi CoinPolarityTE has been dropping without an apparent catalyst since mid-June. A week before it started dropping, a new DeFi coin called Peet DeFi launched using the same symbol as PolarityTE, “PTE”. The “$PTE” cashtag on Twitter has been more or less taken over by Peet DeFi. The prices of both are dropping.分析記事 • Jun 04Does PolarityTE (NASDAQ:PTE) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Recent Insider Transactions • May 21Independent Chairman of the Board recently bought US$259k worth of stockOn the 18th of May, Peter Cohen bought around 265k shares on-market at roughly US$0.98 per share. This was the largest purchase by an insider in the last 3 months. This was Peter's only on-market trade for the last 12 months.Reported Earnings • May 16First quarter 2021 earnings released: US$0.23 loss per share (vs US$0.40 loss in 1Q 2020)The company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2021 results: Revenue: US$4.71m (up 405% from 1Q 2020). Net loss: US$17.4m (loss widened 34% from 1Q 2020).分析記事 • Feb 19What You Need To Know About PolarityTE, Inc.'s (NASDAQ:PTE) Investor CompositionA look at the shareholders of PolarityTE, Inc. ( NASDAQ:PTE ) can tell us which group is most powerful. Institutions...Major Estimate Revision • Feb 16Analysts update estimatesThe 2020 consensus revenue estimate was lowered from US$9.59m to US$9.42m. The company's losses in 2020 are expected to improve with analysts raising their EPS forecasts from -US$1.07 to -US$0.88. The Biotechs industry in the US is expected to see a 1.3% decline in net income next year. The consensus price target of US$3.00 was unchanged from the last update. Share price is up 9.7% to US$1.69 over the past week.Is New 90 Day High Low • Feb 10New 90-day high: US$1.54The company is up 90% from its price of US$0.81 on 11 November 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 23% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$55.68 per share.Is New 90 Day High Low • Jan 09New 90-day high: US$1.32The company is up 22% from its price of US$1.08 on 09 October 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$84.75 per share.Is New 90 Day High Low • Dec 15New 90-day low: US$0.63The company is down 43% from its price of US$1.11 on 15 September 2020. The American market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$11.12 per share.Analyst Estimate Surprise Post Earnings • Nov 11Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 12%. Earnings per share (EPS) missed analyst estimates by 12%. Over the next year, revenue is forecast to grow 26%, compared to a 315% growth forecast for the Biotechs industry in the US.Reported Earnings • Nov 11Third quarter 2020 earnings released: US$0.18 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: US$3.34m (up 139% from 3Q 2019). Net loss: US$7.08m (loss narrowed 69% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has fallen by 67% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Nov 10New 90-day low: US$0.81The company is down 44% from its price of US$1.45 on 11 August 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$9.83 per share.Is New 90 Day High Low • Oct 19New 90-day low: US$1.01The company is down 45% from its price of US$1.85 on 21 July 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$10.35 per share.株主還元RGTP.QUS BiotechsUS 市場7D0.6%2.9%2.5%1Y668.5%33.0%26.4%株主還元を見る業界別リターン: RGTP.Q過去 1 年間で33 % の収益を上げたUS Biotechs業界を上回りました。リターン対市場: RGTP.Q過去 1 年間で26.4 % の収益を上げたUS市場を上回りました。価格変動Is RGTP.Q's price volatile compared to industry and market?RGTP.Q volatilityRGTP.Q Average Weekly Movement40.1%Biotechs Industry Average Movement10.8%Market Average Movement7.2%10% most volatile stocks in US Market16.5%10% least volatile stocks in US Market3.1%安定した株価: RGTP.Qの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: RGTP.Qの 週次ボラティリティ は過去 1 年間で81%から40%に減少しましたが、依然としてUS株の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/an/aRichard Haguewww.polaritybio.com臨床段階のバイオテクノロジー企業であるRegenETP, Inc.は、米国において医療、生体医工学、材料科学の各分野に向けた様々な再生組織製品および生体材料の開発・商業化を行なっている。同社は、再生医療製品と受託サービスの2つのセグメントで事業を展開している。同社は、急性または慢性の創傷、火傷、外科的再建イベント、瘢痕修正、機能不全に陥った皮膚移植片の除去などの治療において、患者の皮膚の修復、再建、置換、補填に使用される組織製品SkinTEや、受託研究サービスを提供している。同社はまた、凍結保存プロセスにより1回の採取から複数回の移植を可能にするSkinTE Cryoや、最初の採取後すぐにSkinTEを処理・移植するためのPOC（ポイント・オブ・ケア）装置、その他の組織再生製品も開発している。同社は以前はPolarityTE, Inc.として知られていたが、2023年8月にRegenETP, Inc.に社名を変更した。本社はユタ州ソルトレイクシティ。もっと見るRegenETP, Inc. 基礎のまとめRegenETP の収益と売上を時価総額と比較するとどうか。RGTP.Q 基礎統計学時価総額US$1.12m収益（TTM）-US$8.30m売上高(TTM)US$73.00k0.0xP/Sレシオ0.0xPER（株価収益率RGTP.Q は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計RGTP.Q 損益計算書（TTM）収益US$73.00k売上原価US$125.00k売上総利益-US$52.00kその他の費用US$8.25m収益-US$8.30m直近の収益報告Mar 31, 2023次回決算日該当なし一株当たり利益（EPS）0グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0.0%RGTP.Q の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/04/18 10:10終値2025/04/16 00:00収益2023/03/31年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋RegenETP, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関Kristen KluskaCantor Fitzgerald & Co.Joshua SchimmerEvercore ISISwayampakula RamakanthH.C. Wainwright & Co.6 その他のアナリストを表示
お知らせ • May 21RegenETP, Inc. announced that it expects to receive $22.5 million in funding from Avenue Capital Group, LLCRegenETP, Inc. has announced that it will receive $12.5 million in a round of funding on May 20, 2024. The company will issue Common shares for the gross proceeds of $12.5 million from institutional investors and current shareholders in the transaction. The company will be provided remaining gross proceeds of $10 million in senior secured credit facility from Avenue Venture Opportunities Fund, L.P., a fund managed by Avenue Capital Group, LLC. As on the same date, the company has received $17.5 million in its first tranche. The company has received $12.5 million for the common shares and $5 million for the senior secured credit facility.
お知らせ • Feb 27PolarityTE Screens First Subject in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot UlcersPolarityTE announced the Screening of the first subject in the Phase III pivotal study evaluating SkinTE in the investigational treatment of Wagner grade 1 diabetic foot ulcers (DFUs), entitled "Closure Obtained with Vascularized Epithelial Regeneration for DFUs with SkinTE II," or "COVER DFUS II." COVER DFUS II will enroll up to 120 subjects at up to 20 clinical sites in the United States. Subjects will be randomized to one of two treatment groups, receiving either SkinTE plus the standard of care (SOC) or the SOC alone. The primary endpoint is the incidence of DFUs closed at 12 weeks. Secondary endpoints include percent area reduction (PAR) at 4, 8, and 12 weeks; Total number of in-person wound care clinic visits and/or hospital days related to the index ulcer from Randomization Visit (RV1); Total days of CAM Boot use related to the index ulcer from Randomization Visit (RV1); Time to closure within 24 weeks; and Proportion of subjects experiencing treatment-emergent AEs between SOC and SkinTE arms. COVER DFUS II is a pivotal study that PolarityTE will conduct under its open IND for SkinTE.
お知らせ • Aug 19+ 1 more updatePolarityTE, Inc. Announces Resignation of Jacob Patterson as Chief Financial OfficerOn August 18, 2023, Jacob Patterson, Chief Financial Officer of RegenETP, Inc. (formerly known as PolarityTE, Inc.), a Delaware corporation, informed the Company of his decision to resign effective immediately in order to pursue other opportunities.
お知らせ • Aug 17+ 1 more updatePolarityTE, Inc. announced delayed 10-Q filingOn 08/15/2023, PolarityTE, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 12PolarityTE, Inc. Files Form 15PolarityTE, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.001 per share.
お知らせ • Jul 08Nasdaq to Delist the Common Stock of PolarityTENasdaq announced on July 06, 2023 that it will delist the common stock of PolarityTE, Inc. The company’s securities were suspended on June 16, 2023, and have not traded on Nasdaq since that time.
お知らせ • May 21RegenETP, Inc. announced that it expects to receive $22.5 million in funding from Avenue Capital Group, LLCRegenETP, Inc. has announced that it will receive $12.5 million in a round of funding on May 20, 2024. The company will issue Common shares for the gross proceeds of $12.5 million from institutional investors and current shareholders in the transaction. The company will be provided remaining gross proceeds of $10 million in senior secured credit facility from Avenue Venture Opportunities Fund, L.P., a fund managed by Avenue Capital Group, LLC. As on the same date, the company has received $17.5 million in its first tranche. The company has received $12.5 million for the common shares and $5 million for the senior secured credit facility.
お知らせ • Feb 27PolarityTE Screens First Subject in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot UlcersPolarityTE announced the Screening of the first subject in the Phase III pivotal study evaluating SkinTE in the investigational treatment of Wagner grade 1 diabetic foot ulcers (DFUs), entitled "Closure Obtained with Vascularized Epithelial Regeneration for DFUs with SkinTE II," or "COVER DFUS II." COVER DFUS II will enroll up to 120 subjects at up to 20 clinical sites in the United States. Subjects will be randomized to one of two treatment groups, receiving either SkinTE plus the standard of care (SOC) or the SOC alone. The primary endpoint is the incidence of DFUs closed at 12 weeks. Secondary endpoints include percent area reduction (PAR) at 4, 8, and 12 weeks; Total number of in-person wound care clinic visits and/or hospital days related to the index ulcer from Randomization Visit (RV1); Total days of CAM Boot use related to the index ulcer from Randomization Visit (RV1); Time to closure within 24 weeks; and Proportion of subjects experiencing treatment-emergent AEs between SOC and SkinTE arms. COVER DFUS II is a pivotal study that PolarityTE will conduct under its open IND for SkinTE.
お知らせ • Aug 19+ 1 more updatePolarityTE, Inc. Announces Resignation of Jacob Patterson as Chief Financial OfficerOn August 18, 2023, Jacob Patterson, Chief Financial Officer of RegenETP, Inc. (formerly known as PolarityTE, Inc.), a Delaware corporation, informed the Company of his decision to resign effective immediately in order to pursue other opportunities.
お知らせ • Aug 17+ 1 more updatePolarityTE, Inc. announced delayed 10-Q filingOn 08/15/2023, PolarityTE, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 12PolarityTE, Inc. Files Form 15PolarityTE, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.001 per share.
お知らせ • Jul 08Nasdaq to Delist the Common Stock of PolarityTENasdaq announced on July 06, 2023 that it will delist the common stock of PolarityTE, Inc. The company’s securities were suspended on June 16, 2023, and have not traded on Nasdaq since that time.
お知らせ • Jun 17PolarityTE, Inc.(OTCPK:PTEI.Q) dropped from NASDAQ Composite IndexPolarityTE, Inc. removed
New Risk • Jun 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$22m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Shareholders have been substantially diluted in the past year (87% increase in shares outstanding). Revenue is less than US$1m (US$73k revenue). Market cap is less than US$10m (US$1.44m market cap).
お知らせ • Jun 09+ 1 more updatePolarityTE's Common Stock To Be Delisted From NasdaqAs previously disclosed, on June 6, 2023, PolarityTE, Inc. (Company) and certain of its subsidiaries (collectively, the “Debtors”) filed voluntary petitions for relief (the “Chapter 11 Cases”) under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the District of Utah (Bankruptcy Court) under the captions In re PolarityTE, Inc., a Delaware corporation (Case No. 23-bk-22358-KRA) (Bankr. D. Utah), In re PolarityTE, MD Inc., a Nevada corporation (Case No. 23-bk-22360-KRA) (Bankr. D. Utah), and In re PolarityTE, Inc., a Nevada corporation (Case No. 23-bk-22361-KRA) (Bankr. D. Utah) (collectively, the “Chapter 11 Cases”). The Debtors have filed a motion with the Bankruptcy Court seeking joint administration under the caption In re PolarityTE, Inc., a Delaware corporation (Case No. 23-bk-22358-KRA) (Bankr. D. Utah). On June 7, 2023, the Company received written notice (the “Delisting Notice”) from the staff of the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, as a result of the Chapter 11 Cases and in accordance with Nasdaq Listing Rules 5101, 5110(b), and IM-5101-1, Nasdaq had determined that the Company’s common stock will be delisted from Nasdaq. The Company does not intend to appeal this determination. In addition, as previously disclosed, on October 26, 2022, the Company received a deficiency letter (the “Bid Price Notice”) from the Staff notifying the Company that the Company was not in compliance with the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In the Delisting Notice, the staff of Nasdaq referenced concerns about the Company’s ability to sustain compliance with all requirements for continued listing on Nasdaq, specifically referencing the Bid Price Notice. Trading of the Company’s common stock will be suspended at the opening of business on June 16, 2023.
Reported Earnings • May 14First quarter 2023 earnings released: US$0.58 loss per share (vs US$1.12 loss in 1Q 2022)First quarter 2023 results: US$0.58 loss per share. Net loss: US$4.24m (loss widened 13% from 1Q 2022). Revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US.
Reported Earnings • Mar 29Full year 2022 earnings: EPS misses analyst expectationsFull year 2022 results: US$1.14 loss per share (improved from US$9.43 loss in FY 2021). Net loss: US$7.83m (loss narrowed 74% from FY 2021). Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US.
お知らせ • Jan 28Polarityte, Inc. Appoints Jeff Dyer as A Member of the Board of DirectorsPolarityTE, Inc. elected Jeff Dyer, PhD, to serve as a member of the Board of Directors beginning January 26, 2023, for a term expiring at the Company’s 2025 annual meeting of stockholders. Dr. Dyer was also appointed to serve on the Company’s Audit Committee, Nominating and Governance Committee, and Compensation Committee for which he will also serve as chairperson. Dr. Dyer served on the Company’s Board from March 2, 2017, to September 2, 2022. Dr. Dyer has served as the Horace Beesley Professor of Strategy at Brigham Young University since September 1999. From August 1993 until September 1999, he served as an Assistant Professor at Wharton School, University of Pennsylvania, and from July 1984 until September 1988 he served as Management Consultant and Manager of Bain & Company. Dr. Dyer received his Bachelor of Science degree in psychology and MBA from Brigham Young University and his PhD in management from University of California, Los Angeles. In consideration for Dr. Dyer’s agreement to join the Board the Company agreed to pay him a one-time cash fee of $10,000. In accordance with the Company’s annual compensation program for non-employee directors that began October 1, 2022, Dr. Dyer is entitled to receive a $50,000 annual retainer prorated for the period of actual service that began January 26, 2023, or a total of $33,972.60, which is paid in the form of restricted stock units issued under the Company’s equity incentive plans that will vest in arrears at the rate of 26.2% on March 31, 2023, 36.9% on June 30, 2023, and 36.9% on September 30, 2023. Dr. Dyer will be entitled be entitled to additional compensation for his service on Board committees. As chair of the Compensation Committee he is paid an annual cash fee of $7,500, payable quarterly in arrears and prorated for actual periods of service less than a full quarter. As a member of the Audit Committee Dr. Dyer is paid an annual cash fee of $4,500 and as a member of the Nominating and Governance Committee he is paid an annual cash fee of $2,500, in each case payable quarterly in arrears and prorated for periods of service less than a full quarter.
Board Change • Jan 19Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. Independent Chairman of the Board Peter Cohen was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Breakeven Date Change • Jan 03Forecast to breakeven in 2025The 2 analysts covering PolarityTE expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$42.5m in 2025. Average annual earnings growth of 58% is required to achieve expected profit on schedule.
Major Estimate Revision • Nov 17Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 losses forecast to reduce from -US$130 to -US$4.60 per share. Revenue forecast unchanged from US$814.0k at last update. Biotechs industry in the US expected to see average net income decline 94% next year. Consensus price target of US$1.25 unchanged from last update. Share price fell 16% to US$0.69 over the past week.
Price Target Changed • Nov 16Price target decreased to US$1.25Down from US$50.00, the current price target is provided by 1 analyst. New target price is 80% above last closing price of US$0.69. The company is forecast to post a net loss per share of US$4.60 next year compared to a net loss per share of US$9.43 last year.
Reported Earnings • Nov 16Third quarter 2022 earnings released: US$0.47 loss per share (vs US$0.31 loss in 3Q 2021)Third quarter 2022 results: US$0.47 loss per share (further deteriorated from US$0.31 loss in 3Q 2021). Net loss: US$3.40m (loss widened 233% from 3Q 2021). Revenue is expected to decline by 145% p.a. on average during the next 2 years, while revenues in the Biotechs industry in the US are expected to grow by 14%.
Reported Earnings • Nov 12Third quarter 2022 earnings released: US$0.47 loss per share (vs US$0.31 loss in 3Q 2021)Third quarter 2022 results: US$0.47 loss per share (further deteriorated from US$0.31 loss in 3Q 2021). Net loss: US$3.40m (loss widened 233% from 3Q 2021). Revenue is expected to decline by 145% p.a. on average during the next 2 years, while revenues in the Biotechs industry in the US are expected to grow by 14%.
Major Estimate Revision • Aug 18Consensus revenue estimates fall by 40%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$2.20m to US$1.32m. Forecast losses increased from -US$0.98 to -US$9.15 per share. Biotechs industry in the US expected to see average net income decline 57% next year. Consensus price target of US$39.38 unchanged from last update. Share price fell 19% to US$1.32 over the past week.
Price Target Changed • Aug 13Price target decreased to US$15.38Down from US$26.88, the current price target is an average from 3 analysts. New target price is 1,014% above last closing price of US$1.38. Stock is down 93% over the past year. The company is forecast to post a net loss per share of US$0.66 next year compared to a net loss per share of US$9.43 last year.
Reported Earnings • Aug 12Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2022 results: US$0.013 loss per share (up from US$0.99 loss in 2Q 2021). Revenue: US$73.0k (down 97% from 2Q 2021). Net loss: US$68.0k (loss narrowed 98% from 2Q 2021). Revenue missed analyst estimates by 85%. Earnings per share (EPS) exceeded analyst estimates by 98%. Over the next year, revenue is expected to shrink by 17% compared to a 51% growth forecast for the industry in the US.
Seeking Alpha • Aug 12PolarityTE down 10% on lower-than-expected Q2 revenuePolarityTE (NASDAQ:PTE) is trading ~10% down after the company reported lower-than-expected quarterly revenue. The company said it ceased commercial sales of SkinTE in the second calendar quarter of 2021 and sold the IBEX services business, so the Company was not engaged in any revenue generating business activity at June 30, and does not expect to generate operating revenues from any business activity for the foreseeable future. The Company had cash and cash equivalents of $20.5m
Major Estimate Revision • May 23Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$2.82m to US$2.20m. EPS estimate increased from -US$6.75 to -US$0.98 per share. Biotechs industry in the US expected to see average net income decline 52% next year. Consensus price target down from US$26.88 to US$15.38. Share price fell 43% to US$2.43 over the past week.
Price Target Changed • May 22Price target decreased to US$15.38Down from US$26.88, the current price target is an average from 3 analysts. New target price is 554% above last closing price of US$2.35. Stock is down 92% over the past year. The company is forecast to post a net loss per share of US$0.98 next year compared to a net loss per share of US$9.43 last year.
Reported Earnings • May 17First quarter 2022 earnings: Revenues miss analyst expectationsFirst quarter 2022 results: Revenue: US$741.0k (down 84% from 1Q 2021). Net loss: US$3.77m (loss narrowed 78% from 1Q 2021). Revenue missed analyst estimates by 13%. Over the next year, revenue is expected to shrink by 47% compared to a 36% growth forecast for the industry in the US.
Price Target Changed • Apr 27Price target decreased to US$1.08Down from US$2.25, the current price target is an average from 3 analysts. New target price is 478% above last closing price of US$0.19. Stock is down 82% over the past year. The company is forecast to post a net loss per share of US$0.27 next year compared to a net loss per share of US$0.38 last year.
Major Estimate Revision • Apr 06Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$2.87m to US$2.82m. 2022 losses expected to reduce from -US$0.34 to -US$0.27 per share. Biotechs industry in the US expected to see average net income decline 47% next year. Consensus price target down from US$2.25 to US$1.08. Share price fell 15% to US$0.23 over the past week.
Reported Earnings • Mar 31Full year 2021 earnings: EPS and revenues exceed analyst expectationsFull year 2021 results: US$0.38 loss per share (up from US$1.11 loss in FY 2020). Revenue: US$9.40m (down 7.1% from FY 2020). Net loss: US$30.2m (loss narrowed 30% from FY 2020). Revenue exceeded analyst estimates by 16%. Earnings per share (EPS) also surpassed analyst estimates by 20%. Over the next year, revenue is expected to shrink by 74% compared to a 66% growth forecast for the pharmaceuticals industry in the US.
分析記事 • Mar 08Will PolarityTE (NASDAQ:PTE) Spend Its Cash Wisely?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Nov 16Here's Why We're Watching PolarityTE's (NASDAQ:PTE) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Reported Earnings • Nov 12Third quarter 2021 earnings released: US$0.013 loss per share (vs US$0.18 loss in 3Q 2020)The company reported a decent third quarter result with reduced losses and improved control over expenses, although revenues were weaker. Third quarter 2021 results: Revenue: US$1.12m (down 67% from 3Q 2020). Net loss: US$1.02m (loss narrowed 86% from 3Q 2020).
Executive Departure • Sep 07Independent Director Minnie Baylor-Henry has left the companyOn the 1st of September, Minnie Baylor-Henry's tenure as Independent Director ended after 2.7 years in the role. As of June 2021, Minnie still personally held 129.51k shares (US$132k worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 3.17 years.
Major Estimate Revision • Aug 19Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$11.1m to US$7.69m. EPS estimate increased from -US$0.52 to -US$0.45 per share. Biotechs industry in the US expected to see average net income decline 21% next year. Consensus price target of US$2.75 unchanged from last update. Share price fell 5.0% to US$0.82 over the past week.
Reported Earnings • Aug 14Second quarter 2021 earnings released: US$0.04 loss per share (vs US$0.33 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: US$2.54m (up 12% from 2Q 2020). Net loss: US$3.19m (loss narrowed 75% from 2Q 2020).
Seeking Alpha • Jul 19PolarityTE Is Not A DeFi CoinPolarityTE has been dropping without an apparent catalyst since mid-June. A week before it started dropping, a new DeFi coin called Peet DeFi launched using the same symbol as PolarityTE, “PTE”. The “$PTE” cashtag on Twitter has been more or less taken over by Peet DeFi. The prices of both are dropping.
分析記事 • Jun 04Does PolarityTE (NASDAQ:PTE) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Recent Insider Transactions • May 21Independent Chairman of the Board recently bought US$259k worth of stockOn the 18th of May, Peter Cohen bought around 265k shares on-market at roughly US$0.98 per share. This was the largest purchase by an insider in the last 3 months. This was Peter's only on-market trade for the last 12 months.
Reported Earnings • May 16First quarter 2021 earnings released: US$0.23 loss per share (vs US$0.40 loss in 1Q 2020)The company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2021 results: Revenue: US$4.71m (up 405% from 1Q 2020). Net loss: US$17.4m (loss widened 34% from 1Q 2020).
分析記事 • Feb 19What You Need To Know About PolarityTE, Inc.'s (NASDAQ:PTE) Investor CompositionA look at the shareholders of PolarityTE, Inc. ( NASDAQ:PTE ) can tell us which group is most powerful. Institutions...
Major Estimate Revision • Feb 16Analysts update estimatesThe 2020 consensus revenue estimate was lowered from US$9.59m to US$9.42m. The company's losses in 2020 are expected to improve with analysts raising their EPS forecasts from -US$1.07 to -US$0.88. The Biotechs industry in the US is expected to see a 1.3% decline in net income next year. The consensus price target of US$3.00 was unchanged from the last update. Share price is up 9.7% to US$1.69 over the past week.
Is New 90 Day High Low • Feb 10New 90-day high: US$1.54The company is up 90% from its price of US$0.81 on 11 November 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 23% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$55.68 per share.
Is New 90 Day High Low • Jan 09New 90-day high: US$1.32The company is up 22% from its price of US$1.08 on 09 October 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$84.75 per share.
Is New 90 Day High Low • Dec 15New 90-day low: US$0.63The company is down 43% from its price of US$1.11 on 15 September 2020. The American market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$11.12 per share.
Analyst Estimate Surprise Post Earnings • Nov 11Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 12%. Earnings per share (EPS) missed analyst estimates by 12%. Over the next year, revenue is forecast to grow 26%, compared to a 315% growth forecast for the Biotechs industry in the US.
Reported Earnings • Nov 11Third quarter 2020 earnings released: US$0.18 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: US$3.34m (up 139% from 3Q 2019). Net loss: US$7.08m (loss narrowed 69% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has fallen by 67% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Nov 10New 90-day low: US$0.81The company is down 44% from its price of US$1.45 on 11 August 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$9.83 per share.
Is New 90 Day High Low • Oct 19New 90-day low: US$1.01The company is down 45% from its price of US$1.85 on 21 July 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$10.35 per share.
